- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
First Helium
CI Galaxy Bitcoin ETF
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Naturally Splendid Closes Full Spectrum Amended Licence Deal
Naturally Splendid (TSXV:NSP) announced it has closed the restated and amended licence agreement with Full Spectrum Laboratories Ltd. (FSL), a company controlled by Charles R. Brink, a director of Naturally Splendid, whereby the parties amended the terms of the licence agreement dated Nov. 17, 2015.
Naturally Splendid (TSXV:NSP) announced it has closed the restated and amended licence agreement with Full Spectrum Laboratories Ltd. (FSL), a company controlled by Charles R. Brink, a director of Naturally Splendid, whereby the parties amended the terms of the licence agreement dated Nov. 17, 2015.
As quoted in the press release:
This filing marks the acceptance by the TSX Venture Exchange for the previously announced restated and amended license agreement. As a result of closing of the Restated and Amended License Agreement, Naturally Splendid acquired a one hundred percent (100%) interest, without royalty, in FSL’s omega technologies, including HempOmega(TM) and H2Omega(TM). In addition to hemp, the technology has the potential to transform flax, chia, canola, chia and algae into highly bioavailable water dispersible powders and aqueous solutions. FSL removed the minimum annual royalty of USD $1.6 million (the “Minimum Royalty”) that was set to commence after the second anniversary of the Original License Agreement and continue for ten (10) years for a total reduction of $16,000,000 CDN in guaranteed royalty payments. In consideration of owning a 100% interest in the omega technologies and the removal of the Minimum Royalty, Naturally Splendid extinguished its non-exclusive license of FSL’s bioreactor technology and changed its exclusive license on certain analytical testing SOPs and GC-MS Terpene Analysis SOPs to a non-exclusive license.
Naturally Splendid’s CEO Craig Goodwin states:
We anticipate that the outright acquisition of the omega technologies will greatly contribute to our corporate strategy of becoming a leading producer of value-added nutritional ingredient solutions. Secured ownership will allow us to explore out-licensing opportunities for HempOmega(TM) and other applications of the omega technologies.”Bryan Carson, Naturally Splendid’s VP of Operations added, “We are continuing to promote HempOmega(TM) as sustainable omega ingredient for the human, pet, livestock, and cosmetic industries. In initial studies, HempOmega(TM) demonstrated higher sustainability and bioavailability than unformulated omega oils. Our researchers will also begin to look at other plant oils that may be successfully encapsulated with this technology to create additional bioactive ingredients.
Connect withNaturally Splendid (TSXV:NSP) to receive an Investor Kit
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.